Clinical features of 313 treatments with ibrutinib in patients with CLL at the moment ibrutinib was started
| Clinical feature | Patients (N = 313) |
| Male sex, n (%) | 189 (61) |
| Age, median (range), y | 67 (35-95) |
| Binet (available for 245 [78%]), n (%) | |
| A | 102/245 (42) |
| B | 89/245 (37) |
| C | 52/245 (21) |
| Elevated β2-microglobulin (available in 118 [38%]), n (%) | 57/118 (48) |
| Unmutated IGHV (available in 101 [31%]), n (%) | 70/101 (69) |
| FISH for del17p positive and/or TP53 mutation present (available in 191 [62%]), n (%) | 40/191 (21) |
| Line of therapy, n (%) | |
| First | 77 (25) |
| Second | 132 (42) |
| Third | 64 (20) |
| Fourth or further lines | 40 (13) |
| Duration of ibrutinib, median (range) | 29 mo (6 d to116 mo) |
| Clinical feature | Patients (N = 313) |
| Male sex, n (%) | 189 (61) |
| Age, median (range), y | 67 (35-95) |
| Binet (available for 245 [78%]), n (%) | |
| A | 102/245 (42) |
| B | 89/245 (37) |
| C | 52/245 (21) |
| Elevated β2-microglobulin (available in 118 [38%]), n (%) | 57/118 (48) |
| Unmutated IGHV (available in 101 [31%]), n (%) | 70/101 (69) |
| FISH for del17p positive and/or TP53 mutation present (available in 191 [62%]), n (%) | 40/191 (21) |
| Line of therapy, n (%) | |
| First | 77 (25) |
| Second | 132 (42) |
| Third | 64 (20) |
| Fourth or further lines | 40 (13) |
| Duration of ibrutinib, median (range) | 29 mo (6 d to116 mo) |
FISH, fluorescence in situ hybridization.